Pfizer Inc (PFE)

$26.97 -0.44 (-1.61%)
Market Cap 153.36B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.49
Forward PE 9.22
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 66,805,600
Avg Vol 47,041,215
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 36%
Beta 0.47
Analysts Sell
Price Target $28.94

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
indepth1
indepth1 Mar. 23 at 2:36 PM
$DRMA Notice of Allowance :: Product Details & NEW Applications ;; ((AI Research & my DD as scientist )) 🔑 "Patent focuses on Dermata’s core Spongilla technology,🌞 (( specifically targeting treatment of Acne Conglobata. )) >>>$DRMA will help 2 other types of inflammatory skin diseases that 23 million people have in just USA. that are new FIRST TIME CUSTOMERS. <<<🌞 Expansion of Existing Tech: This is an Addition to their existing intellectual property (IP) portfolio. 🔑 While it ✅️ utilizes their established Spongilla (sponge-derived) platform, the allowed claims > > > specifically Cover New Therapeutic applications and dosage forms that were NOT Protected under their previous patents. < < <✅️= IMPORTANT Mechanism: 👍 $DRMA's NEW technology uses a 🌞 Unique mechanical stimulation and delivery system to penetrate the skin barrier and deliver active ingredients Deeper into the dermis 🌞 without the need for harsh chemicals."👍 (( 👍 👍 Huge New Applications for use of $DRMA on >> > 2 other skin diseases that can ONLY be controlled with ongoing treatments that 23 million people in just USA have as on going issues that need this new product. 👍👍 )) 🌞 🌞 Bullish on ORS Meeting 3-28 to 3-31 is the Meeting for big Pharma like $PFE will be wanting/Requiring new license and funding deals in this Huge meeting of near 2600 presenting companies in show!!🌞 🌞 Buyer of more at $1.37 0n retrace on 3-23.
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 23 at 2:26 PM
LYME VACCINE: THE NEXT BIG INFECTIOUS DISEASE PLAY 👉Click to view @NasdaqKnight for timely updates amid the volatility. 476,000+ cases/year in the US. 300M+ at-risk in US/EU. No vaccine since 2002. That's about to change. $PFE — THE LEADER VLA15 (w/ Valneva) is the ONLY Phase 3 Lyme vaccine candidate Data readout: 1H 2026 (literally any day now) If approved: First-to-market in a $1B+ market $MRNA — THE CHALLENGER mRNA-1975/1982 in Phase 1/2 2026 catalysts: flu vaccine approval, flu/COVID combo, RSV data Cash position: $8.1B — ready to invest $BNTX — THE PLATFORM mRNA powerhouse. Oncology lead, but infectious disease pipeline in the wings The Setup: Lyme is the next major vaccine battleground. $PFE is months away from potentially owning it. $MRNA is right behind with mRNA tech. $BNTX is watching from the wings. Phase 3 data could drop any week. Don't sleep on this.
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 23 at 2:17 PM
$PFE - Roses are red, my cat puked on my carpet, we are Pfizer and we always inverse the Market 🥀
0 · Reply
markbrogan
markbrogan Mar. 23 at 2:17 PM
$PFE Ted to green today, it almost too obvious !
0 · Reply
topstockalerts
topstockalerts Mar. 23 at 2:12 PM
Pfizer will seek FDA approval for its Lyme disease vaccine despite missing the late-stage trial’s statistical goal, citing “strong efficacy” with a >70% infection reduction in vaccinated participants. The trial was limited by too few infections to achieve statistical significance. Pfizer’s partner Valneva estimates peak annual sales could exceed $1B, though it’s a small fraction of Pfizer’s expected $60B revenue for 2026. The vaccine uses the outer surface protein A of Lyme bacteria, creating antibodies that block transmission from ticks. No safety concerns were reported. The move may test U.S. vaccine regulatory scrutiny, given the vaccine technically failed the trial. Lyme disease affects ~500,000 Americans annually, and no human vaccine currently exists. $PFE
0 · Reply
Pfizer
Pfizer Mar. 23 at 2:10 PM
$PFE Pfizer and Valneva SE today announced topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating strong efficacy. LB6V demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above, and was well tolerated with no safety concerns identified at time of analysis. Overall, these results strengthen our confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities. Read more: https://investors.pfizer.com/Investors/News/news-details/2026/Pfizer-and-Valneva-Announce-Lyme-Disease-Vaccine-Candidate-Demonstrates-Strong-Efficacy-in-Phase-3-VALOR-Trial/default.aspx
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 23 at 1:53 PM
$PFE
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 23 at 1:51 PM
$PFE genuinely what is wrong with this stock
0 · Reply
Voronina_IR
Voronina_IR Mar. 23 at 1:37 PM
$PFE defensive money can hide here and if rotation turns cautious this may see quiet accumulation
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 23 at 1:36 PM
$PFE both of my stocks are red, fucking cheers
0 · Reply
Latest News on PFE
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 1 hour ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 3 hours ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 3 hours ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 3 hours ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 3 hours ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 1 day ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 2 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 4 days ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 4 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer: I'm Still Expecting A Massive Rebound

Mar 18, 2026, 9:00 AM EDT - 5 days ago

Pfizer: I'm Still Expecting A Massive Rebound

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 6 days ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 6 days ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation

Mar 13, 2026, 5:01 PM EDT - 9 days ago

Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 14 days ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 14 days ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

Mar 7, 2026, 8:15 AM EST - 16 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

ADP ARCC BX CAG GLPI MPLX MSFT

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

Mar 6, 2026, 6:05 AM EST - 17 days ago

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

AMD GOOG GOOGL LLY NVDA NVO

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 17 days ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 17 days ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 18 days ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR ARE BBY BEN BXP CAG CCI

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

Mar 4, 2026, 9:09 AM EST - 19 days ago

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 19 days ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Pfizer's Quiet Cash Comeback

Mar 3, 2026, 9:50 AM EST - 19 days ago

Pfizer's Quiet Cash Comeback

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 20 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:27 PM EST - 20 days ago

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 20 days ago

Pfizer CEO flags issues with FDA's vaccine leadership

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 21 days ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

ABBV AMGN AVGO BTI DIV ENB GTY

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

Mar 1, 2026, 8:10 AM EST - 22 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

ARCC BBVA E EQNR ETD FINV GSL

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 23 days ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

Feb 26, 2026, 7:48 AM EST - 25 days ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 26 days ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 27 days ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 27 days ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 27 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 27 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 4 weeks ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 4 weeks ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 4 weeks ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 4 weeks ago

Pfizer: The Rebound Looks Unsustainable

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 4 weeks ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 5 weeks ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 5 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 6:08 PM EST - 5 weeks ago

Pfizer: A Great Opportunity Post Earnings

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 5 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 5 weeks ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 5 weeks ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 8, 2026, 10:19 PM EST - 6 weeks ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 6 weeks ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

Feb 6, 2026, 7:25 AM EST - 6 weeks ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 6 weeks ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

indepth1
indepth1 Mar. 23 at 2:36 PM
$DRMA Notice of Allowance :: Product Details & NEW Applications ;; ((AI Research & my DD as scientist )) 🔑 "Patent focuses on Dermata’s core Spongilla technology,🌞 (( specifically targeting treatment of Acne Conglobata. )) >>>$DRMA will help 2 other types of inflammatory skin diseases that 23 million people have in just USA. that are new FIRST TIME CUSTOMERS. <<<🌞 Expansion of Existing Tech: This is an Addition to their existing intellectual property (IP) portfolio. 🔑 While it ✅️ utilizes their established Spongilla (sponge-derived) platform, the allowed claims > > > specifically Cover New Therapeutic applications and dosage forms that were NOT Protected under their previous patents. < < <✅️= IMPORTANT Mechanism: 👍 $DRMA's NEW technology uses a 🌞 Unique mechanical stimulation and delivery system to penetrate the skin barrier and deliver active ingredients Deeper into the dermis 🌞 without the need for harsh chemicals."👍 (( 👍 👍 Huge New Applications for use of $DRMA on >> > 2 other skin diseases that can ONLY be controlled with ongoing treatments that 23 million people in just USA have as on going issues that need this new product. 👍👍 )) 🌞 🌞 Bullish on ORS Meeting 3-28 to 3-31 is the Meeting for big Pharma like $PFE will be wanting/Requiring new license and funding deals in this Huge meeting of near 2600 presenting companies in show!!🌞 🌞 Buyer of more at $1.37 0n retrace on 3-23.
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 23 at 2:26 PM
LYME VACCINE: THE NEXT BIG INFECTIOUS DISEASE PLAY 👉Click to view @NasdaqKnight for timely updates amid the volatility. 476,000+ cases/year in the US. 300M+ at-risk in US/EU. No vaccine since 2002. That's about to change. $PFE — THE LEADER VLA15 (w/ Valneva) is the ONLY Phase 3 Lyme vaccine candidate Data readout: 1H 2026 (literally any day now) If approved: First-to-market in a $1B+ market $MRNA — THE CHALLENGER mRNA-1975/1982 in Phase 1/2 2026 catalysts: flu vaccine approval, flu/COVID combo, RSV data Cash position: $8.1B — ready to invest $BNTX — THE PLATFORM mRNA powerhouse. Oncology lead, but infectious disease pipeline in the wings The Setup: Lyme is the next major vaccine battleground. $PFE is months away from potentially owning it. $MRNA is right behind with mRNA tech. $BNTX is watching from the wings. Phase 3 data could drop any week. Don't sleep on this.
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 23 at 2:17 PM
$PFE - Roses are red, my cat puked on my carpet, we are Pfizer and we always inverse the Market 🥀
0 · Reply
markbrogan
markbrogan Mar. 23 at 2:17 PM
$PFE Ted to green today, it almost too obvious !
0 · Reply
topstockalerts
topstockalerts Mar. 23 at 2:12 PM
Pfizer will seek FDA approval for its Lyme disease vaccine despite missing the late-stage trial’s statistical goal, citing “strong efficacy” with a >70% infection reduction in vaccinated participants. The trial was limited by too few infections to achieve statistical significance. Pfizer’s partner Valneva estimates peak annual sales could exceed $1B, though it’s a small fraction of Pfizer’s expected $60B revenue for 2026. The vaccine uses the outer surface protein A of Lyme bacteria, creating antibodies that block transmission from ticks. No safety concerns were reported. The move may test U.S. vaccine regulatory scrutiny, given the vaccine technically failed the trial. Lyme disease affects ~500,000 Americans annually, and no human vaccine currently exists. $PFE
0 · Reply
Pfizer
Pfizer Mar. 23 at 2:10 PM
$PFE Pfizer and Valneva SE today announced topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating strong efficacy. LB6V demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above, and was well tolerated with no safety concerns identified at time of analysis. Overall, these results strengthen our confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities. Read more: https://investors.pfizer.com/Investors/News/news-details/2026/Pfizer-and-Valneva-Announce-Lyme-Disease-Vaccine-Candidate-Demonstrates-Strong-Efficacy-in-Phase-3-VALOR-Trial/default.aspx
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 23 at 1:53 PM
$PFE
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 23 at 1:51 PM
$PFE genuinely what is wrong with this stock
0 · Reply
Voronina_IR
Voronina_IR Mar. 23 at 1:37 PM
$PFE defensive money can hide here and if rotation turns cautious this may see quiet accumulation
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 23 at 1:36 PM
$PFE both of my stocks are red, fucking cheers
0 · Reply
kylevallans
kylevallans Mar. 23 at 1:16 PM
Market Bullets: Futures rise after U.S.-Iran talks, ICE to be deployed to airports, CBS News lays off 6% of its staff $PARA.X $BRK.B $BRK.A $PFE $VALN View the free newsletter here: https://stockanalysis.com/market-bullets/2026-03-23/?ref=saveontrading
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 23 at 1:14 PM
$TNXP $PFE good news and target validation for tonix tnx-4800. https://pharmaphorum.com/news/pfizer-valneva-shrug-phase-3-lyme-disease-vaccine-miss
1 · Reply
notreload_ai
notreload_ai Mar. 23 at 1:12 PM
$PFE and $VALN reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions. https://notreload.xyz/pfizer-valneva-lyme-vaccine-shows-73-efficacy-in-phase-3/
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 23 at 12:02 PM
$PFE lol?
1 · Reply
CapitalSignalWorks
CapitalSignalWorks Mar. 23 at 11:43 AM
$PFE’s Lyme vaccine shows 73% efficacy—but “confounded” results from low case counts send partner $VLA plunging -13% in Paris. Despite missing formal trial criteria, Pfizer is pushing ahead with regulatory submission, targeting a booming market: 476K US cases/year. HHS Sec. RFK Jr. has flagged Lyme as a top priority. Bulls see a potential blockbuster if approval sticks.
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 23 at 11:42 AM
$VALN (-35.1% pre) $PFE Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle - STAT https://ooc.bz/l/96880
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 23 at 10:53 AM
$PFE - Good news, huh? Bring on the red!
0 · Reply
DonCorleone77
DonCorleone77 Mar. 23 at 10:50 AM
$PFE $VALN Pfizer, Valneva announce 'positive' results from Phase 3 VALOR trial Pfizer (PFE) and Valneva (VALN) announced topline results from the Phase 3 VALOR clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: In the pre-specified analyses: Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm; Efficacy of 74.8% from 1-day post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm; Fewer than anticipated Lyme disease cases were accrued over the study period, and the pre-determined statistical criterion was not met in the first pre-specified analysis. Given the clinically meaningful efficacy and the fact that the 95% confidence interval lower bound was above 20 in the second pre-specified analysis, Pfizer is confident in the vaccine's potential and is planning submissions to regulatory authorities.
0 · Reply
Quantumup
Quantumup Mar. 23 at 10:47 AM
Citizens reiterated $IDYA Market Outperform; $45 $PFE $XBI XLO IBRX Citizens said in its note—Positive mPFS data from the Ph2 portion of the registrational study in HLA-negative mUM will enable accelerated approval filing for the darovasertib + crizotinib combination in the U.S. IDYA's mUM program has FDA Fast Track and Orphan Drug Designations, which have the potential for meaningfully shortened regulatory timelines. We believe this is a key catalyst for IDYA shares in 2026 that will mark the transition to a commercial-stage company. Shares have only appreciated 12% (vs. +11% for XBI) since SMRC incrementally de-risked the OS readout in mUM, and since the PFS readout in neoadjuvant at ESMO. We believe this leaves significant upside on the table given the data and into the binary catalyst. We have strong confidence in a positive readout (90% POS) and believe shares could gain 10-30%.
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 23 at 9:43 AM
Opioid Crisis KILLER? $VRTX & $PFE Just Dropped a NON-ADDICTIVE BOMB! 👉Click to view @NasdaqKnight for timely updates amid the volatility. The future of pain management is here, and it’s NOT opioids. While the market sleeps on this $81B+ opportunity , the biotech giants are quietly building the next growth super-cycle. $VRTX is the star player. After that recent pullback to ~$454 (down ~5% last month) , it’s looking JUICY. Why? Their non-opioid pain drug JOURNAVX (NaV1.8 inhibitor) is a game-changer. Plus, they just dropped bullish kidney data (povetacicept) and are filing with the FDA this month for accelerated approval . Analysts see a fair value of $592—that’s a 30% upside from here ! $PFE is the forgotten giant trading at a DISCOUNT ($26.97) . Volume is exploding (142% above avg) . They are aggressively pivoting to non-opioid and oncology. With a $28.14 avg price target and a 5.4% CAGR projected for the pain market , the risk/reward here is asymmetric.
0 · Reply
itsallaboutheoptions
itsallaboutheoptions Mar. 23 at 6:21 AM
$PFE call flow building with stock at $26.92. +965 PFE 100 17 APR 2026 26.00 CALL @ 1.86, for $179,490 total deltas. $179,490 × $26.92 = $4,831,661 in dollar exposure. Near-the-money call into April — someone positioning for a bounce in Pfizer ahead of earnings May 5. 14-Day Trial! Get in now for SMS alerts, market data, and full chat access before the next move hits → https://stkt.co/CIvyqh6l
0 · Reply
TradeTracs
TradeTracs Mar. 23 at 12:49 AM
🚨 After-Hours Movers Alert! 🚨 XPeng ( $XPEV ) 🔋 Turned green in after-hours despite missing revenue estimates — EV rebound vibes? 📈 Bristol-Myers Squibb ( $BMY ) 💊 Up +0.6% as pharma strength holds steady Pfizer ( $PFE ) 💉 In focus amid ongoing sector watch Big names making moves while the market digests the week! 📊 Who are you eyeing? 👀 #Stocks #AfterHours #XPEV #BMY #PFE
0 · Reply